Valuation Laboratorios Farmaceuticos Rovi, S.A. Wiener Boerse

Stocks

End-of-day quote Wiener Boerse 21/08/2026			5-day change	1st Jan Change
59.60 ^EUR	-1.57%		+2.14%	-5.85%

23/07	Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026
23/07	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	4,138	1,925	3,213	3,220	3,248	3,063	-	-
Change	-	-53.49%	66.93%	0.22%	0.87%	-5.68%	-	-
Enterprise Value (EV) ¹	4,112	1,872	3,251	3,305	3,272	3,047	2,982	2,870
Change	-	-54.48%	73.7%	1.65%	-1%	-6.86%	-2.14%	-3.76%
P/E	26.7x	9.67x	18.8x	23.6x	23.1x	21.4x	17.7x	14.4x
PBR	8.59x	3.71x	5.94x	5.63x	4.89x	4.1x	3.48x	2.98x
PEG	-	0.3x	-1.3x	-1.4x	7.71x	12.99x	0.8x	0.6x
Capitalization / Revenue	6.38x	2.35x	3.87x	4.22x	4.37x	3.97x	3.44x	3.14x
EV / Revenue	6.34x	2.29x	3.92x	4.33x	4.4x	3.95x	3.35x	2.94x
EV / EBITDA	20.3x	6.72x	13.3x	15.9x	15.1x	15.5x	11.5x	9.23x
EV / EBIT	22.7x	7.32x	14.8x	18.4x	17.6x	18.6x	13.3x	10.5x
EV / FCF	37.9x	10.1x	54.3x	43.5x	27.4x	16.5x	24x	17.4x
FCF Yield	2.64%	9.95%	1.84%	2.3%	3.65%	6.05%	4.17%	5.75%
Dividend per Share ²	0.9556	1.294	1.104	0.9351	0.9594	0.963	1.169	1.354
Rate of return	1.29%	3.59%	1.83%	1.49%	1.51%	1.61%	1.95%	2.26%
EPS ²	2.76	3.73	3.2	2.67	2.75	2.795	3.388	4.146
Distribution rate	34.6%	34.7%	34.5%	35%	34.9%	34.5%	34.5%	32.6%
Net sales ¹	648.7	817.7	829.5	763.7	743.5	771.7	890.8	976.1
EBITDA ¹	202.9	278.7	244.5	207.4	216.2	196.3	258.6	310.9
EBIT ¹	181.5	255.8	220.1	179.4	185.8	163.5	223.7	274.4
Net income ¹	153.1	199.7	170.3	136.9	140.4	128.5	173.9	212.8
Net Debt ¹	-25.87	-52.78	38.6	85.1	23.84	-16.21	-81.51	-193.5
Reference price ²	73.80	36.06	60.20	62.95	63.50	59.80	59.80	59.80
Nbr of stocks (in thousands)	56,069	53,375	53,370	51,149	51,149	51,143	-	-
Announcement Date	23/02/22	21/02/23	27/02/24	25/02/25	24/02/26	-	-	-

¹EUR in Million²EUR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	35.55x	12.84x	26.06x	0.55%	1,10900Cr
JOHNSON & JOHNSON	29.74x	-	-	2.01%	64TCr
ABBVIE INC.	33.42x	7.74x	16.11x	2.62%	46TCr
ROCHE HOLDING AG	20.72x	4.91x	12.16x	2.69%	37TCr
NOVARTIS AG	22.47x	5.78x	14.33x	2.76%	30TCr
ASTRAZENECA PLC	21.12x	4.35x	12.35x	2.02%	26TCr
AMGEN INC.	27.43x	7.09x	12.59x	2.33%	23TCr
NOVO NORDISK A/S	13.47x	4.79x	10.05x	3.81%	20TCr
GILEAD SCIENCES, INC.	-43.83x	6.34x	24.76x	2.3%	18TCr
Average	17.79x	6.73x	16.05x	2.34%	41.79TCr
Weighted average by Cap.	25.34x	8.43x	18.53x	1.91%